Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, Chuenchitra T, Garner RP, Thapinta D, Polonis V, Ratto-Kim S, Chanbancherd P, Chiu J, Birx DL, Duliege AM, McNeil JG, Brown AE; Thai AIDS Vaccine Evaluation Group. Pitisuttithum P, et al. Among authors: duliege am. J Infect Dis. 2003 Jul 15;188(2):219-27. doi: 10.1086/376506. Epub 2003 Jul 3. J Infect Dis. 2003. PMID: 12854076 Clinical Trial.
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, Chuenchitra C, Supapongse T, Rungruengthanakit K, deSouza M, Mascola JR, Boggio K, Ratto-Kim S, Markowitz LE, Birx D, Suriyanon V, McNeil JG, Brown AE, Michael RA. Nitayaphan S, et al. Among authors: duliege am. Vaccine. 2000 Feb 14;18(15):1448-55. doi: 10.1016/s0264-410x(99)00421-1. Vaccine. 2000. PMID: 10618542 Clinical Trial.
Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1.
Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel SS, DeSouza MS, Polonis V, McLinden R, Sambor A, Brown AE, Phonrat B, Rungruengthanakit K, Duliege AM, Robb ML, McNeil J, Birx DL; Thai AIDS Vaccine Evaluation Group. Kim JH, et al. Among authors: duliege am. AIDS Res Hum Retroviruses. 2003 Sep;19(9):807-16. doi: 10.1089/088922203769232601. AIDS Res Hum Retroviruses. 2003. PMID: 14585211 Clinical Trial.
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S. Zolla-Pazner S, et al. Among authors: duliege am. J Infect Dis. 1997 Apr;175(4):764-74. doi: 10.1086/513969. J Infect Dis. 1997. PMID: 9086128 Clinical Trial.
Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA; AIDS Clinical Trials Group 230 Collaborators. McFarland EJ, et al. Among authors: duliege am. J Infect Dis. 2001 Nov 15;184(10):1331-5. doi: 10.1086/323994. Epub 2001 Oct 10. J Infect Dis. 2001. PMID: 11679925 Clinical Trial.
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Belshe RB, et al. Among authors: duliege am. J Infect Dis. 2001 May 1;183(9):1343-52. doi: 10.1086/319863. Epub 2001 Apr 10. J Infect Dis. 2001. PMID: 11294665 Clinical Trial.
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E. Borkowsky W, et al. Among authors: duliege am. J Infect Dis. 2000 Mar;181(3):890-6. doi: 10.1086/315298. J Infect Dis. 2000. PMID: 10720509 Clinical Trial.
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W; Pediatric AIDS Clinical Trials Group 230 Collaborators. Cunningham CK, et al. Among authors: duliege am. Clin Infect Dis. 2001 Mar 1;32(5):801-7. doi: 10.1086/319215. Epub 2001 Feb 28. Clin Infect Dis. 2001. PMID: 11229849 Clinical Trial.
53 results